iSAH group N = 8 | Hem. inf. group N = 15 | |
---|---|---|
Age (mean ± SD) | 49.3 ± 16.2 | 47.9 ± 16.8 |
Gender | 6 M, 2 W | 4 M, 11 W |
Genetic thrombophilia (%) | 4 (50.0%) | 2 (13.3%) |
Acquired thrombophilia (%) | 0 (0%) | 4 (26.7%) |
Autoimmune disorder (%) | 4 (50.0%) | 4 (26.7%) |
Hypothyroid disorder (%) | 1 (12.5%) | 1 (6.7%) |
Venous sinuses injury (%) | 1 (12.5%) | 0 (0%) |
Malignancy (%) | 1 (12.5%) | 1 (6.7%) |
Pregnancy (%) | 0 (0%) | 1 (6.7%) |
Glucocorticoid/sex steroid therapy (%) | 1 (12.5%) | 6 (40.0%) |
iSAH group N = 8 | Hem. Inf group N = 15 | |
---|---|---|
Headache (%) | 6 (75.0%) | 9 (60.0%) |
Seizure (%) | 3 (37.5%) | 8 (53.3%) |
Focal signs (%) | 2 (25.0%) | 5 (33.3%) |
Nausea/vomiting (%) | 2 (25.0%) | 3 (20.0%) |
Confusion (%) | 0 (0%) | 2 (13.3%) |
Disturbed consciousness(%) | 0 (0%) | 4 (26.7%) |
iSAH group N = 8 | Hem. Inf group N = 15 | |
---|---|---|
Average No. of thrombosed CVS (median, 25%, 75% percentiles) | 4 (25% 3.25, 75% 5.75) | 2 (25% 1, 75% 3)* |
Sulcal obliteration | 0 (0.0%) | 13 (86.7%)* |
Subfalcine/uncal herniation | 0 (0.0%) | 4 (26.7%) |
Oedema formation | 2 (25.0%) | 8 (53.3%)* |
Average mRS at discharge (median, 25% , 75% percentiles) | 1 (25% 0, 75% 1.75) | 2 (25% 0, 75% 3) |
Average mRS at control (median, 25% , 75% percentiles) | 0 (25% 0, 75% 0) | 1 (25% 0, 75% 3)* |